EverPoint Asset Management’s AstraZeneca AZN Stock Holding History

EverPoint Asset Management’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$16.4M	Buy	+300,000	New	+$17M	0.3%	87
2015 Q2	–	Sell	-145,000	Closed	-$9.92M	–	449
2015 Q1	$9.92M	Sell	145,000 -78,500	-35%	-$5.45M	0.19%	171
2014 Q4	$15.7M	Buy	223,500 +123,500	+124%	+$8.84M	0.35%	95
2014 Q3	$7.14M	Sell	100,000 -160,000	-62%	-$11.7M	0.16%	206
2014 Q2	$19.3M	Buy	+260,000	New	+$18.8M	0.4%	56

Other funds holding AZN

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

EIP

Epoch Investment Partners New York $16.5B AUM 24.3% 1-Year Est. Return

BIM

BlackRock Investment Management Wilmington, Delaware $86.4B AUM 16.83% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

EverPoint Asset Management's AZN Position: Q4 2016 in Review

EverPoint Asset Management opened a new position in AstraZeneca (AZN) in Q4 2016: 300,000 shares worth $16.4M. The stake represents 0.3% of the portfolio and ranks #87 among its holdings. This is a return to the name: EverPoint Asset Management previously reported a position in AZN as recently as Q1 2015.

EverPoint Asset Management first reported a position in AZN in Q2 2014 and has held it in 5 quarters since. The position peaked at $19.3M in Q2 2014. 450 funds tracked by Wall St. Rank hold AZN as of Q4 2016.

EverPoint Asset Management held 300,000 shares of AstraZeneca worth $16.4M as of Q4 2016.
AstraZeneca was a new EverPoint Asset Management position in Q4 2016.
AstraZeneca made up 0.3% of EverPoint Asset Management's portfolio in Q4 2016, its #87 holding.
EverPoint Asset Management first reported a position in AstraZeneca in Q2 2014 and has held it in 5 quarters since.
EverPoint Asset Management's AstraZeneca position peaked at $19.3M in Q2 2014.
450 funds tracked by Wall St. Rank held AstraZeneca as of Q4 2016.

Based on EverPoint Asset Management's 13F filing for Q4 2016, filed 14 Feb 2017.